Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs) EQUITY
$71.31
pos +0.00
+0.00%
Today's Range: 70.71 - 71.54 | BMY Avg Daily Volume: 6,004,900
Last Update: 05/27/16 - 4:00 PM EDT
Volume: 0
YTD Performance: 3.66%
Open: $0.00
Previous Close: $70.73
52 Week Range: $51.82 - $73.06
Oustanding Shares: 1,669,307,273
Market Cap: 118,070,103,419
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 6 6 6
Moderate Buy 1 1 1 1
Hold 7 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 2 2 1 0
Mean Rec. 2.32 2.37 2.18 1.96
Latest Dividend: 0.38
Latest Dividend Yield: 2.13%
Dividend Ex-Date: 03/30/16
Price Earnings Ratio: 35.44
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
35.44 75.90 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
14.55% 4.25% 50.44%
GROWTH 12 Mo 3 Yr CAGR
Revenue 4.30 -0.10 -0.02
Net Income -19.60 -0.30 -0.13
EPS -22.30 -0.20 -0.07
Earnings for BMY:
EBITDA 2.27B
Revenue 16.56B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.65 $0.64 $2.60 $3.35
Number of Analysts 7 5 10 9
High Estimate $0.68 $0.69 $2.71 $3.68
Low Estimate $0.64 $0.61 $2.50 $3.01
Prior Year $0.53 $0.39 $2.01 $2.60
Growth Rate (Year over Year) 23.45% 64.10% 29.35% 28.97%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

bullishBristol-Myers numbers raised at Jefferies

May 5, 2016 | 6:52 AM EDT

Shares of BMY now seen reaching $75, according to Jefferies. Estimates also increased, givne a faster expected ramp for the Opdivo monotherapy. Hold rating. 

updateBMY Investor Mtg.

May 3, 2016 | 7:04 AM EDT

BMY - Bristol-Myers Squibb Co Annual Shareholders Meeting - 10AM

By

Jim Cramer

 | May 2, 2016 | 7:04 AM EDT

It's mighty tough to put a multiple on a declining business.

By

Gary Morrow

 | Apr 28, 2016 | 3:04 PM EDT

The drug maker is approaching overbought territory, but is set up well for more upside.

By

Bruce Kamich

 | Apr 28, 2016 | 2:23 PM EDT

We recently got a golden cross of the 50-day and 200-day averages.

By

Jim Cramer

 | Apr 28, 2016 | 11:11 AM EDT

Jim Cramer believes the pharmaceutical sector has come full circle and some of the best stocks in the group are ready to move higher.

By

Mark Newton

 | Apr 22, 2016 | 5:30 AM EDT

bearishBristol-Myers rated new Sell at SocGen

Apr 7, 2016 | 7:47 AM EDT

Coverage of BMY was started with a Sell rating, Societe Generale said. $48 price target. Estimates also below consensus, given lower expectations for Opdivo cancer treatment. 

By

Bruce Kamich

 | Mar 29, 2016 | 11:05 AM EDT

The pharmaceutical company's stock is likely to weaken further if it declines below $61 and $60 in the days ahead.

By

Jim Cramer

 | Mar 22, 2016 | 6:17 AM EDT

The group rallied yesterday, but it's still not out of the woods.

Nice finish today for CVX. The stock has been steadily improving after holding key su...
TMO agreed to purchase FEI Company for S4.2 billion dollars this morning. The company ran ...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.